{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [], "source": [ "import pandas as pd" ] }, { "cell_type": "code", "execution_count": 2, "metadata": {}, "outputs": [], "source": [ "df = pd.read_csv('../ClinicalTrialCSV/JRCT20241129Cancer.csv', index_col=0)" ] }, { "cell_type": "code", "execution_count": 6, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitleTarget研究・治験の目的試験の種類無作為化盲検化対照割付け研究目的...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)Phase
0jRCT1030240513進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...がん進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...介入研究無作為化比較単盲検プラセボ対照並行群間比較緩和...supportive careEligible participants must meet the following ...Exclusion criteria apply if any of the followi...18age old overNo limitNaNNaNcancer,Participants will be exposed to either sounds ...NaN
1jRCT1032240511進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究がん患者の疼痛交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...介入研究単一群非盲検非対照単群比較その他...other1. Age 18 years or older on the day of consent...1. There is a skin disorder in the painful are...18age old overNo limitBothNaNNaNFour pads of the alternating magnetic field th...NaN
2jRCT1032240506卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験卵巣がん卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...介入研究無作為化比較単盲検実薬（治療）対照並行群間比較治療...treatment purposePatients undergoing ovarian cancer surgery at ...1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...18age old over100age old notFemaleNaNNaNLow-pressure ventilation and low venous pressu...NaN
3jRCT2041240130中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...肺がん全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...NaN無作為化比較非盲検無治療対照/標準治療対照並行群間比較治療...treatment purpose(1) Patients scheduled to undergo anatomical l...(1) Patients with a history of allergy to the ...18age old overNo limitBothNaNNaNTreatment group\\n\\r\\nAdminister GRA 1mg intrav...NaN
4jRCT2031240500ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する...ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する...固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...NaN単一群非盲検非対照単群比較治療...treatment purposeParts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...18age old overNo limitBothNaNNaNDrug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitorNaN
..................................................................
282jRCT2080223823固形がん患者を対象としたE7130 の臨床第1相試験Part1：固形がん\\nPart2：頭頸部がん，尿路上皮がんNaN介入研究NaNNaNNaNNaNNaN...NaNNaNNaNNaNNaN<p>Both</p>NaNNaNinvestigational material(s)<br>\\nGeneric name ...NaN
283jRCT1090220266肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討肺がんNaNNaNNaN非盲検実薬（治療）対照なしNaN...NaNNaNNaNAge Month Week Day HourAge Month Week Day Hour No limitBothNaNNaNIntervention type:BEHAVIOUR\\n\\nName of interve...NaN
284jRCT1091220254肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討肺がんNaNNaNNaN単盲検用量比較ありNaN...NaNNaNNaNAge Month Week Day Hour No limitAge Month Week Day Hour No limitBothNaNNaNIntervention type:DRUG\\n\\nName of intervention...NaN
285jRCT1090220224体幹部神経ブロック後のレボブピバカインの血中濃度の変化下腹部消化器がんNaNNaNNaN非盲検無対照NaNNaN...NaNNaNNaN20Age Month Week Day Hour overAge Month Week Day Hour No limitBothNaNNaNIntervention type:\\n\\nName of intervention:\\n\\...NaN
286jRCT1091220221ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...肺がんNaNNaNNaN非盲検無対照なしNaN...NaNNaNNaNAge Month Week Day Hour No limitAge Month Week Day Hour No limitBothNaNNaNIntervention type:DRUG\\n\\nName of intervention...NaN
\n", "

287 rows × 35 columns

\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "0 jRCT1030240513 進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探... \n", "1 jRCT1032240511 進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究 \n", "2 jRCT1032240506 卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験 \n", "3 jRCT2041240130 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... \n", "4 jRCT2031240500 ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する... \n", ".. ... ... \n", "282 jRCT2080223823 固形がん患者を対象としたE7130 の臨床第1相試験 \n", "283 jRCT1090220266 肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討 \n", "284 jRCT1091220254 肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討 \n", "285 jRCT1090220224 体幹部神経ブロック後のレボブピバカインの血中濃度の変化 \n", "286 jRCT1091220221 ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効... \n", "\n", " Target \\\n", "0 がん \n", "1 がん患者の疼痛 \n", "2 卵巣がん \n", "3 肺がん \n", "4 ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する... \n", ".. ... \n", "282 Part1：固形がん\\nPart2：頭頸部がん，尿路上皮がん \n", "283 肺がん \n", "284 肺がん \n", "285 下腹部消化器がん \n", "286 肺がん \n", "\n", " 研究・治験の目的 試験の種類 無作為化 盲検化 \\\n", "0 進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲... 介入研究 無作為化比較 単盲検 \n", "1 交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時... 介入研究 単一群 非盲検 \n", "2 卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す... 介入研究 無作為化比較 単盲検 \n", "3 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... NaN 無作為化比較 非盲検 \n", "4 固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持... NaN 単一群 非盲検 \n", ".. ... ... ... ... \n", "282 NaN 介入研究 NaN NaN \n", "283 NaN NaN NaN 非盲検 \n", "284 NaN NaN NaN 単盲検 \n", "285 NaN NaN NaN 非盲検 \n", "286 NaN NaN NaN 非盲検 \n", "\n", " 対照 割付け 研究目的 ... purpose \\\n", "0 プラセボ対照 並行群間比較 緩和 ... supportive care \n", "1 非対照 単群比較 その他 ... other \n", "2 実薬（治療）対照 並行群間比較 治療 ... treatment purpose \n", "3 無治療対照/標準治療対照 並行群間比較 治療 ... treatment purpose \n", "4 非対照 単群比較 治療 ... treatment purpose \n", ".. ... ... ... ... ... \n", "282 NaN NaN NaN ... NaN \n", "283 実薬（治療）対照 なし NaN ... NaN \n", "284 用量比較 あり NaN ... NaN \n", "285 無対照 NaN NaN ... NaN \n", "286 無対照 なし NaN ... NaN \n", "\n", " Inclusion Criteria \\\n", "0 Eligible participants must meet the following ... \n", "1 1. Age 18 years or older on the day of consent... \n", "2 Patients undergoing ovarian cancer surgery at ... \n", "3 (1) Patients scheduled to undergo anatomical l... \n", "4 Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H... \n", ".. ... \n", "282 NaN \n", "283 NaN \n", "284 NaN \n", "285 NaN \n", "286 NaN \n", "\n", " Exclusion Criteria \\\n", "0 Exclusion criteria apply if any of the followi... \n", "1 1. There is a skin disorder in the painful are... \n", "2 1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie... \n", "3 (1) Patients with a history of allergy to the ... \n", "4 Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha... \n", ".. ... \n", "282 NaN \n", "283 NaN \n", "284 NaN \n", "285 NaN \n", "286 NaN \n", "\n", " Age Minimum Age Maximum \\\n", "0 18age old over No limit \n", "1 18age old over No limit \n", "2 18age old over 100age old not \n", "3 18age old over No limit \n", "4 18age old over No limit \n", ".. ... ... \n", "282 NaN NaN \n", "283 Age Month Week Day Hour Age Month Week Day Hour No limit \n", "284 Age Month Week Day Hour No limit Age Month Week Day Hour No limit \n", "285 20Age Month Week Day Hour over Age Month Week Day Hour No limit \n", "286 Age Month Week Day Hour No limit Age Month Week Day Hour No limit \n", "\n", " Gender Discontinuation Criteria Keyword \\\n", "0 NaN NaN cancer, \n", "1 Both NaN NaN \n", "2 Female NaN NaN \n", "3 Both NaN NaN \n", "4 Both NaN NaN \n", ".. ... ... ... \n", "282

Both

NaN NaN \n", "283 Both NaN NaN \n", "284 Both NaN NaN \n", "285 Both NaN NaN \n", "286 Both NaN NaN \n", "\n", " Intervention(s) Phase \n", "0 Participants will be exposed to either sounds ... NaN \n", "1 Four pads of the alternating magnetic field th... NaN \n", "2 Low-pressure ventilation and low venous pressu... NaN \n", "3 Treatment group\\n\\r\\nAdminister GRA 1mg intrav... NaN \n", "4 Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor NaN \n", ".. ... ... \n", "282 investigational material(s)
\\nGeneric name ... NaN \n", "283 Intervention type:BEHAVIOUR\\n\\nName of interve... NaN \n", "284 Intervention type:DRUG\\n\\nName of intervention... NaN \n", "285 Intervention type:\\n\\nName of intervention:\\n\\... NaN \n", "286 Intervention type:DRUG\\n\\nName of intervention... NaN \n", "\n", "[287 rows x 35 columns]" ] }, "execution_count": 6, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df" ] }, { "cell_type": "code", "execution_count": 7, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitleTarget研究・治験の目的試験の種類無作為化盲検化対照割付け研究目的...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)Phase
3jRCT2041240130中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr...肺がん全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro...NaN無作為化比較非盲検無治療対照/標準治療対照並行群間比較治療...treatment purpose(1) Patients scheduled to undergo anatomical l...(1) Patients with a history of allergy to the ...18age old overNo limitBothNaNNaNTreatment group\\n\\r\\nAdminister GRA 1mg intrav...NaN
4jRCT2031240500ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する...ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する...固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持...NaN単一群非盲検非対照単群比較治療...treatment purposeParts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H...Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha...18age old overNo limitBothNaNNaNDrug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitorNaN
9jRCT2031240448切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験切除不能皮膚血管肉腫切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と...NaN単一群非盲検非対照単群比較治療...treatment purpose1)\\tHistologically diagnosed with cutaneous an...1)\\tPatients previously treated with anti-PD-1...18age old over85age old underBothNaNcutaneous angiosarcoma, angiosarcomaEach course is set at 21 days. Pembrolizumab 2...NaN
12jRCT2031240404転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4...・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳...サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受...NaN非無作為化比較非盲検用量比較単群比較治療...treatment purpose-Phase 1a (Dose Escalation) and 1b (Dose Expan...-Prior therapy selectively targeting CDK4 (pri...18age old overNo limitBothNaNNaN-Drug: BGB-43395\\n\\r\\nPlanned doses administer...NaN
13jRCT2031240381進行固形がん患者を対象としたGSK5764227の安全性、忍容性、薬物動態、及び有効性を評価...進行固形がんGSK5764227の安全性、忍容性、薬物動態、及び有効性を評価する。評価する。また、GSK...NaN非無作為化比較非盲検非対照単群比較治療...treatment purpose-Male or female participants at least 18 years...-Has ongoing adverse reaction(s) from prior th...18age old overNo limitBothNaNNaNDrug: GSK5764227\\n\\r\\nGSK5764227 will be admin...NaN
..................................................................
238jRCT2033200278MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...多発性骨髄腫【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM...NaN単一群非盲検非対照単群比較治療...treatment purpose-Patients aged between 20 and 80 (75 for the p...-Patients who are scheduled to receive high-do...20age old over80age old underBothNaNNaNOPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...NaN
240jRCT2051200105標準化学療法に不応・不耐かつ外科的切除不能膵がん患者を対\\n象とした、 R-OKY-034F...膵臓がん標準化学療法に不応・不耐かつ外科的切除不能膵がん患者に対して、R-OKY-034Fを1日1回...NaN単一群非盲検非対照単群比較治療...treatment purpose1. Patients who are 20 years old or above at t...1. Patients with active duplicate cancer\\n\\r\\n...20age old overNo limitBothNaNNaNOnce a day for orally\\n\\r\\n1mg/kg, 2.5mg/kg, 5...NaN
242jRCT20712000601 種類以上の全身療法を含む 2種類以上の治療で失敗、あるいは治療中または治療後に病勢進行が...頭頸部扁平上皮がん1種類以上の全身療法を含む2種類以上の治療で失敗、あるいは治療中また は治療後に病勢進行した...NaN無作為化比較非盲検実薬（治療）対照並行群間比較治療...treatment purposePatients must meet the following criteria to b...Patients with any of the following will be exc...18age old overNo limitBothNaNNaNASP-1929 640mg/m^2 intravenous infusion by dri...NaN
257jRCT2033190086悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第...悪性黒色腫第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ...NaN単一群非盲検非対照単群比較治療...treatment purpose(Phase 1)\\n\\r\\n1) Histologically confirmed mal...(Phase 1 and 2)\\n\\r\\n1) Patients who have brai...20age old overNo limitBothNaNmalignamt melanoma, advanced stageTest drug (T-hIL12) will be administered into ...NaN
261jRCT2051190009進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体...進行性悪性黒色腫抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010...NaN非無作為化比較非盲検非対照単群比較治療...treatment purposeInclusion criteria \\n\\r\\nPatients meeting all ...Exclusion criteria\\n\\r\\nPatients meeting any o...20age old over86age old notBothNaNadvanced melanomacombination therapy of intracutaneous GEN0101 ...NaN
\n", "

124 rows × 35 columns

\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "3 jRCT2041240130 中等度-高度PONV発症リスクを有する肺切除術予定患者の周術期管理におけるGranisetr... \n", "4 jRCT2031240500 ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する... \n", "9 jRCT2031240448 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験 \n", "12 jRCT2031240404 転移性HR+/HER2-乳がん及びその他の進行性固形がん患者を対象にCDK4阻害剤BGB-4... \n", "13 jRCT2031240381 進行固形がん患者を対象としたGSK5764227の安全性、忍容性、薬物動態、及び有効性を評価... \n", ".. ... ... \n", "238 jRCT2033200278 MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効... \n", "240 jRCT2051200105 標準化学療法に不応・不耐かつ外科的切除不能膵がん患者を対\\n象とした、 R-OKY-034F... \n", "242 jRCT2071200060 1 種類以上の全身療法を含む 2種類以上の治療で失敗、あるいは治療中または治療後に病勢進行が... \n", "257 jRCT2033190086 悪性黒色腫患者を対象としたインターロイキン12発現型遺伝子組換え単純ヘルペスウイルス１型の第... \n", "261 jRCT2051190009 進行性悪性黒色腫患者を対象としたGEN0101の皮内投与と、ペムブロリズマブ（抗PD-1抗体... \n", "\n", " Target \\\n", "3 肺がん \n", "4 ミスマッチ修復機能欠損（dMMR）又は高頻度マイクロサテライト不安定性（MSI-H）を有する... \n", "9 切除不能皮膚血管肉腫 \n", "12 ・進行性固形腫瘍・進行性乳がん・転移性乳がん・ホルモン受容体陽性乳がん・ホルモン受容体陽性乳... \n", "13 進行固形がん \n", ".. ... \n", "238 多発性骨髄腫 \n", "240 膵臓がん \n", "242 頭頸部扁平上皮がん \n", "257 悪性黒色腫 \n", "261 進行性悪性黒色腫 \n", "\n", " 研究・治験の目的 試験の種類 無作為化 盲検化 \\\n", "3 全身麻酔を要する肺切除術周術期における標準制吐療法であるグラニセトロン(Granisetro... NaN 無作為化比較 非盲検 \n", "4 固形がんは、体のさまざまな部位に発生する異常な組織の塊である。本治験は、特定の遺伝的特徴を持... NaN 単一群 非盲検 \n", "9 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と... NaN 単一群 非盲検 \n", "12 サイクリン依存性キナーゼ 4 (CDK4) 阻害剤である BGB-43395 が、ホルモン受... NaN 非無作為化比較 非盲検 \n", "13 GSK5764227の安全性、忍容性、薬物動態、及び有効性を評価する。評価する。また、GSK... NaN 非無作為化比較 非盲検 \n", ".. ... ... ... ... \n", "238 【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM... NaN 単一群 非盲検 \n", "240 標準化学療法に不応・不耐かつ外科的切除不能膵がん患者に対して、R-OKY-034Fを1日1回... NaN 単一群 非盲検 \n", "242 1種類以上の全身療法を含む2種類以上の治療で失敗、あるいは治療中また は治療後に病勢進行した... NaN 無作為化比較 非盲検 \n", "257 第Ⅰ相パート：進行期の悪性黒色腫患者を対象として、ヒトIL-12発現型遺伝子組換え単純ヘルペ... NaN 単一群 非盲検 \n", "261 抗PD-1抗体治療でSDが確定した、またはPDとなった患者を対象とし、非盲検下でGEN010... NaN 非無作為化比較 非盲検 \n", "\n", " 対照 割付け 研究目的 ... purpose \\\n", "3 無治療対照/標準治療対照 並行群間比較 治療 ... treatment purpose \n", "4 非対照 単群比較 治療 ... treatment purpose \n", "9 非対照 単群比較 治療 ... treatment purpose \n", "12 用量比較 単群比較 治療 ... treatment purpose \n", "13 非対照 単群比較 治療 ... treatment purpose \n", ".. ... ... ... ... ... \n", "238 非対照 単群比較 治療 ... treatment purpose \n", "240 非対照 単群比較 治療 ... treatment purpose \n", "242 実薬（治療）対照 並行群間比較 治療 ... treatment purpose \n", "257 非対照 単群比較 治療 ... treatment purpose \n", "261 非対照 単群比較 治療 ... treatment purpose \n", "\n", " Inclusion Criteria \\\n", "3 (1) Patients scheduled to undergo anatomical l... \n", "4 Parts 1, 2, and 3 inclusion criteria: \\n\\r\\n-H... \n", "9 1)\\tHistologically diagnosed with cutaneous an... \n", "12 -Phase 1a (Dose Escalation) and 1b (Dose Expan... \n", "13 -Male or female participants at least 18 years... \n", ".. ... \n", "238 -Patients aged between 20 and 80 (75 for the p... \n", "240 1. Patients who are 20 years old or above at t... \n", "242 Patients must meet the following criteria to b... \n", "257 (Phase 1)\\n\\r\\n1) Histologically confirmed mal... \n", "261 Inclusion criteria \\n\\r\\nPatients meeting all ... \n", "\n", " Exclusion Criteria Age Minimum \\\n", "3 (1) Patients with a history of allergy to the ... 18age old over \n", "4 Parts 1, 2, and 3 exclusion criteria:\\n\\r\\n-Ha... 18age old over \n", "9 1)\\tPatients previously treated with anti-PD-1... 18age old over \n", "12 -Prior therapy selectively targeting CDK4 (pri... 18age old over \n", "13 -Has ongoing adverse reaction(s) from prior th... 18age old over \n", ".. ... ... \n", "238 -Patients who are scheduled to receive high-do... 20age old over \n", "240 1. Patients with active duplicate cancer\\n\\r\\n... 20age old over \n", "242 Patients with any of the following will be exc... 18age old over \n", "257 (Phase 1 and 2)\\n\\r\\n1) Patients who have brai... 20age old over \n", "261 Exclusion criteria\\n\\r\\nPatients meeting any o... 20age old over \n", "\n", " Age Maximum Gender Discontinuation Criteria \\\n", "3 No limit Both NaN \n", "4 No limit Both NaN \n", "9 85age old under Both NaN \n", "12 No limit Both NaN \n", "13 No limit Both NaN \n", ".. ... ... ... \n", "238 80age old under Both NaN \n", "240 No limit Both NaN \n", "242 No limit Both NaN \n", "257 No limit Both NaN \n", "261 86age old not Both NaN \n", "\n", " Keyword \\\n", "3 NaN \n", "4 NaN \n", "9 cutaneous angiosarcoma, angiosarcoma \n", "12 NaN \n", "13 NaN \n", ".. ... \n", "238 NaN \n", "240 NaN \n", "242 NaN \n", "257 malignamt melanoma, advanced stage \n", "261 advanced melanoma \n", "\n", " Intervention(s) Phase \n", "3 Treatment group\\n\\r\\nAdminister GRA 1mg intrav... NaN \n", "4 Drug: GSK4418959\\n\\r\\nDrug:PD-1 inhibitor NaN \n", "9 Each course is set at 21 days. Pembrolizumab 2... NaN \n", "12 -Drug: BGB-43395\\n\\r\\nPlanned doses administer... NaN \n", "13 Drug: GSK5764227\\n\\r\\nGSK5764227 will be admin... NaN \n", ".. ... ... \n", "238 OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\... NaN \n", "240 Once a day for orally\\n\\r\\n1mg/kg, 2.5mg/kg, 5... NaN \n", "242 ASP-1929 640mg/m^2 intravenous infusion by dri... NaN \n", "257 Test drug (T-hIL12) will be administered into ... NaN \n", "261 combination therapy of intracutaneous GEN0101 ... NaN \n", "\n", "[124 rows x 35 columns]" ] }, "execution_count": 7, "metadata": {}, "output_type": "execute_result" } ], "source": [ "df.dropna(subset=['試験等のフェーズ'])" ] }, { "cell_type": "code", "execution_count": 8, "metadata": {}, "outputs": [], "source": [ "nan_rows_df = df[df['試験等のフェーズ'].isna()]" ] }, { "cell_type": "code", "execution_count": 9, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitleTarget研究・治験の目的試験の種類無作為化盲検化対照割付け研究目的...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)Phase
0jRCT1030240513進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探...がん進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲...介入研究無作為化比較単盲検プラセボ対照並行群間比較緩和...supportive careEligible participants must meet the following ...Exclusion criteria apply if any of the followi...18age old overNo limitNaNNaNcancer,Participants will be exposed to either sounds ...NaN
1jRCT1032240511進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究がん患者の疼痛交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時...介入研究単一群非盲検非対照単群比較その他...other1. Age 18 years or older on the day of consent...1. There is a skin disorder in the painful are...18age old overNo limitBothNaNNaNFour pads of the alternating magnetic field th...NaN
2jRCT1032240506卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験卵巣がん卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す...介入研究無作為化比較単盲検実薬（治療）対照並行群間比較治療...treatment purposePatients undergoing ovarian cancer surgery at ...1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie...18age old over100age old notFemaleNaNNaNLow-pressure ventilation and low venous pressu...NaN
5jRCT1042240125Liquid Biopsyによる膵がん早期診断法の開発膵嚢胞、慢性膵炎、家族性膵がん及び遺伝性膵がん家族歴を有する症例、糖尿病症例（新規発症・急性...本研究では、膵がん高危険群である膵のう胞性病変等を対象にサーベイランスプログラムを立ち上げ、...観察研究単一群非盲検非対照単群比較診断...diagnostic purpose1. Cases diagnosed as high-risk group for panc...1. Post-Pancreatic Surgery Cases\\n\\r\\n2. Cases...20age old overNo limitBothNaNNaNNaNNaN
6jRCT1052240186トリモーダルプレハビリテーションが周術期の睡眠に及ぼす影響の検討：ランダム化比較試験肺がん術前の介入により、介入群の方が対照群に比べて入院直後の睡眠効率が良いかどうかを検討すること介入研究無作為化比較非盲検無治療対照/標準治療対照単群比較予防...prevention purpose1) Patients aged 20 and over \\n\\r\\n2) Lung can...1) Patients who do not agree \\n\\r\\n2) Patients...20age old overNo limitBothNaNMalignancyIntervention for the Experimental Group:\\n\\r\\n...NaN
..................................................................
282jRCT2080223823固形がん患者を対象としたE7130 の臨床第1相試験Part1：固形がん\\nPart2：頭頸部がん，尿路上皮がんNaN介入研究NaNNaNNaNNaNNaN...NaNNaNNaNNaNNaN<p>Both</p>NaNNaNinvestigational material(s)<br>\\nGeneric name ...NaN
283jRCT1090220266肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討肺がんNaNNaNNaN非盲検実薬（治療）対照なしNaN...NaNNaNNaNAge Month Week Day HourAge Month Week Day Hour No limitBothNaNNaNIntervention type:BEHAVIOUR\\n\\nName of interve...NaN
284jRCT1091220254肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討肺がんNaNNaNNaN単盲検用量比較ありNaN...NaNNaNNaNAge Month Week Day Hour No limitAge Month Week Day Hour No limitBothNaNNaNIntervention type:DRUG\\n\\nName of intervention...NaN
285jRCT1090220224体幹部神経ブロック後のレボブピバカインの血中濃度の変化下腹部消化器がんNaNNaNNaN非盲検無対照NaNNaN...NaNNaNNaN20Age Month Week Day Hour overAge Month Week Day Hour No limitBothNaNNaNIntervention type:\\n\\nName of intervention:\\n\\...NaN
286jRCT1091220221ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効...肺がんNaNNaNNaN非盲検無対照なしNaN...NaNNaNNaNAge Month Week Day Hour No limitAge Month Week Day Hour No limitBothNaNNaNIntervention type:DRUG\\n\\nName of intervention...NaN
\n", "

163 rows × 35 columns

\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "0 jRCT1030240513 進行がん患者に対する可聴領域外のハイレゾ自然音源が与える生体情報や癒しの変化を評価する\\n探... \n", "1 jRCT1032240511 進行がん患者の痛みに対する交番磁界治療器の至適な治療時間の条件に関する多施設共同研究 \n", "2 jRCT1032240506 卵巣腫瘍手術での術中低圧換気介入による術中出血量に及ぼす影響:ランダム化比較試験 \n", "5 jRCT1042240125 Liquid Biopsyによる膵がん早期診断法の開発 \n", "6 jRCT1052240186 トリモーダルプレハビリテーションが周術期の睡眠に及ぼす影響の検討：ランダム化比較試験 \n", ".. ... ... \n", "282 jRCT2080223823 固形がん患者を対象としたE7130 の臨床第1相試験 \n", "283 jRCT1090220266 肺がん手術患者に対する運動療法とBCAA摂取の併用効果の検討 \n", "284 jRCT1091220254 肺動静脈分離3D-CT angiographyにおけるヨード造影剤量低減の検討 \n", "285 jRCT1090220224 体幹部神経ブロック後のレボブピバカインの血中濃度の変化 \n", "286 jRCT1091220221 ヨード造影剤と生理食塩水の混合溶液を用いたtest injectionによる混合割合と造影効... \n", "\n", " Target \\\n", "0 がん \n", "1 がん患者の疼痛 \n", "2 卵巣がん \n", "5 膵嚢胞、慢性膵炎、家族性膵がん及び遺伝性膵がん家族歴を有する症例、糖尿病症例（新規発症・急性... \n", "6 肺がん \n", ".. ... \n", "282 Part1：固形がん\\nPart2：頭頸部がん，尿路上皮がん \n", "283 肺がん \n", "284 肺がん \n", "285 下腹部消化器がん \n", "286 肺がん \n", "\n", " 研究・治験の目的 試験の種類 無作為化 盲検化 \\\n", "0 進行がん患者を対象に、可聴領域外のハイレゾ自然音源を介入とした音楽療法が、無音と比較して、疲... 介入研究 無作為化比較 単盲検 \n", "1 交番磁界治療器を用いた自宅での疼痛治療について、進行がん患者が治療の継続が可能と考える治療時... 介入研究 単一群 非盲検 \n", "2 卵巣悪性腫瘍手術は高侵襲な手術であり輸血率の高い手術である。一方で輸血により癌の予後が悪化す... 介入研究 無作為化比較 単盲検 \n", "5 本研究では、膵がん高危険群である膵のう胞性病変等を対象にサーベイランスプログラムを立ち上げ、... 観察研究 単一群 非盲検 \n", "6 術前の介入により、介入群の方が対照群に比べて入院直後の睡眠効率が良いかどうかを検討すること 介入研究 無作為化比較 非盲検 \n", ".. ... ... ... ... \n", "282 NaN 介入研究 NaN NaN \n", "283 NaN NaN NaN 非盲検 \n", "284 NaN NaN NaN 単盲検 \n", "285 NaN NaN NaN 非盲検 \n", "286 NaN NaN NaN 非盲検 \n", "\n", " 対照 割付け 研究目的 ... purpose \\\n", "0 プラセボ対照 並行群間比較 緩和 ... supportive care \n", "1 非対照 単群比較 その他 ... other \n", "2 実薬（治療）対照 並行群間比較 治療 ... treatment purpose \n", "5 非対照 単群比較 診断 ... diagnostic purpose \n", "6 無治療対照/標準治療対照 単群比較 予防 ... prevention purpose \n", ".. ... ... ... ... ... \n", "282 NaN NaN NaN ... NaN \n", "283 実薬（治療）対照 なし NaN ... NaN \n", "284 用量比較 あり NaN ... NaN \n", "285 無対照 NaN NaN ... NaN \n", "286 無対照 なし NaN ... NaN \n", "\n", " Inclusion Criteria \\\n", "0 Eligible participants must meet the following ... \n", "1 1. Age 18 years or older on the day of consent... \n", "2 Patients undergoing ovarian cancer surgery at ... \n", "5 1. Cases diagnosed as high-risk group for panc... \n", "6 1) Patients aged 20 and over \\n\\r\\n2) Lung can... \n", ".. ... \n", "282 NaN \n", "283 NaN \n", "284 NaN \n", "285 NaN \n", "286 NaN \n", "\n", " Exclusion Criteria \\\n", "0 Exclusion criteria apply if any of the followi... \n", "1 1. There is a skin disorder in the painful are... \n", "2 1.Minors\\n\\r\\n2.Emergency surgery\\n\\r\\n3.Patie... \n", "5 1. Post-Pancreatic Surgery Cases\\n\\r\\n2. Cases... \n", "6 1) Patients who do not agree \\n\\r\\n2) Patients... \n", ".. ... \n", "282 NaN \n", "283 NaN \n", "284 NaN \n", "285 NaN \n", "286 NaN \n", "\n", " Age Minimum Age Maximum \\\n", "0 18age old over No limit \n", "1 18age old over No limit \n", "2 18age old over 100age old not \n", "5 20age old over No limit \n", "6 20age old over No limit \n", ".. ... ... \n", "282 NaN NaN \n", "283 Age Month Week Day Hour Age Month Week Day Hour No limit \n", "284 Age Month Week Day Hour No limit Age Month Week Day Hour No limit \n", "285 20Age Month Week Day Hour over Age Month Week Day Hour No limit \n", "286 Age Month Week Day Hour No limit Age Month Week Day Hour No limit \n", "\n", " Gender Discontinuation Criteria Keyword \\\n", "0 NaN NaN cancer, \n", "1 Both NaN NaN \n", "2 Female NaN NaN \n", "5 Both NaN NaN \n", "6 Both NaN Malignancy \n", ".. ... ... ... \n", "282

Both

NaN NaN \n", "283 Both NaN NaN \n", "284 Both NaN NaN \n", "285 Both NaN NaN \n", "286 Both NaN NaN \n", "\n", " Intervention(s) Phase \n", "0 Participants will be exposed to either sounds ... NaN \n", "1 Four pads of the alternating magnetic field th... NaN \n", "2 Low-pressure ventilation and low venous pressu... NaN \n", "5 NaN NaN \n", "6 Intervention for the Experimental Group:\\n\\r\\n... NaN \n", ".. ... ... \n", "282 investigational material(s)
\\nGeneric name ... NaN \n", "283 Intervention type:BEHAVIOUR\\n\\nName of interve... NaN \n", "284 Intervention type:DRUG\\n\\nName of intervention... NaN \n", "285 Intervention type:\\n\\nName of intervention:\\n\\... NaN \n", "286 Intervention type:DRUG\\n\\nName of intervention... NaN \n", "\n", "[163 rows x 35 columns]" ] }, "execution_count": 9, "metadata": {}, "output_type": "execute_result" } ], "source": [ "nan_rows_df" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }